Chill sweeps over buyout deals after Thoma Bravo cuts price for Anaplan. Who’s next?

“Everything is going to be repriced and prudent investors are going to ensure that they reprice before they make any commitments,” said venture capitalist Ryan Gilbert. Read More...


Hong Kong’s AI drug discovery firm Insilico closes $60M Series D

Insilico Medicine, a Hong Kong-based company that has been using artificial intelligence to discover new drugs since 2014, has completed a fresh round of funding. Insilico raised $60 million from new Series D financing from investors, including its existing shareholders Warburg Pincus, B Capital, Qiming Venture Partners, BOLD Capital Partners, Pavilion Capital and new investors, an undisclosed “large, diversified asset management firm on the West Coast of the US” and BHR Investment. Alex Zhavoronkov, Insilico’s founder and CEO, also participated in the Series D round.

Read More

Add Comment

Click here to post a comment